Roth Capital Expects Weaker Earnings for Fortress Biotech

Fortress Biotech, Inc. (NASDAQ:FBIO) – Analysts at Roth Capital reduced their Q1 2025 earnings per share (EPS) estimates for Fortress Biotech in a report released on Wednesday, April 2nd. Roth Capital analyst J. Wittes now forecasts that the biopharmaceutical company will earn ($0.44) per share for the quarter, down from their prior forecast of $1.47. The consensus estimate for Fortress Biotech’s current full-year earnings is ($3.28) per share. Roth Capital also issued estimates for Fortress Biotech’s Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.64) EPS and FY2026 earnings at ($0.94) EPS.

Separately, Roth Mkm reaffirmed a “buy” rating and set a $16.00 price objective (up from $15.00) on shares of Fortress Biotech in a report on Tuesday, March 11th.

Fortress Biotech Trading Down 2.7 %

FBIO stock opened at $1.43 on Monday. The firm has a 50 day moving average of $1.66 and a 200-day moving average of $1.76. The company has a market cap of $42.23 million, a price-to-earnings ratio of -0.47 and a beta of 1.82. Fortress Biotech has a 12-month low of $1.36 and a 12-month high of $2.89.

Fortress Biotech (NASDAQ:FBIO) last announced its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.53. The company had revenue of $15.12 million during the quarter, compared to analyst estimates of $16.30 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Wolverine Trading LLC acquired a new stake in Fortress Biotech during the 4th quarter valued at $26,000. Weaver Consulting Group lifted its position in shares of Fortress Biotech by 33.0% in the fourth quarter. Weaver Consulting Group now owns 22,998 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 5,700 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Fortress Biotech during the fourth quarter valued at $62,000. Jane Street Group LLC purchased a new stake in Fortress Biotech during the 4th quarter worth about $69,000. Finally, PFG Investments LLC raised its stake in Fortress Biotech by 82.8% in the 4th quarter. PFG Investments LLC now owns 35,259 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 15,968 shares during the last quarter. 96.51% of the stock is owned by hedge funds and other institutional investors.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.